Irinotecan vs non‐irinotecan‐containing regimens: Progression‐free survival (PSF)
Irinotecan showed no clear difference in progression‐free survival ‐ Substitutive comparison compared with non‐irinotecan‐containing regimens (moderate certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Irinotecan vs non‐irinotecan‐containing regimens Progression‐free survival ‐ Substitutive comparison · people with advanced gastric cancer Irinotecan showed no clear difference in progression‐free survival ‐ Substitutive comparison compared with non‐irinotecan‐containing regimens (moderate certainty). Chemotherapy for advanced gastric cancer (2017) · Cochrane Headline outcomes only | HR 0.85 [0.72, 1] | 5 studies · 741 participants | Moderate |
Irinotecan vs non‐irinotecan‐containing regimens Progression‐free survival ‐ Additive comparisons · people with advanced gastric cancer Irinotecan probably leads to lower progression‐free survival ‐ Additive comparisons compared with non‐irinotecan‐containing regimens (moderate certainty). Chemotherapy for advanced gastric cancer (2017) · Cochrane Headline outcomes only | HR 0.51 [0.33, 0.77] | 1 study · 90 participants | Moderate |
Irinotecan vs non‐irinotecan‐containing regimens Progression‐free survival ‐ Other comparisons · people with advanced gastric cancer Irinotecan leads to lower progression‐free survival ‐ Other comparisons compared with non‐irinotecan‐containing regimens (high certainty). Chemotherapy for advanced gastric cancer (2017) · Cochrane Headline outcomes only | HR 0.74 [0.66, 0.84] | 2 studies · 809 participants | High |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.